Amendment to the Claims:

Please amend the claims as follows:

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1. (Currently amended) A method of blocking an immune response to an allogeneic graft in a human, where the human is not suffering from a malignancy, comprising intravenously administering to the ~~mammal~~ human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein after a first intravenous administration of said antibody the circulating levels of B cells in the human are reduced to block said immune response.

2-5. (Cancelled)

6. (Previously presented) The method of claim 1 wherein the antibody is not conjugated with a cytotoxic agent.

7. (Previously presented) The method of claim 1 wherein the antibody comprises rituximab.

8. (Previously presented) The method of claim 1 wherein the antibody is conjugated with a cytotoxic agent.

9. (Original) The method of claim 8 wherein the cytotoxic agent is a radioactive compound.

10. (Previously presented) The method of claim 9 wherein the antibody comprises Y2B8 or ^{131}I-B1.

11. (Cancelled)

12. (Previously presented) The method of claim 1 comprising administering the antibody subcutaneously.

13. (Currently amended) The method of claim 1, ~~comprising administering a~~ wherein each dose ~~of~~ is in the range from about 20mg/m^2 to about 1000mg/m^2 of the antibody to the ~~mammal~~ human.

14. (Currently amended) The method of claim 13 wherein ~~the~~ each dose is in the range from about 20mg/m^2 to about 250mg/m^2.

15. (Currently amended) The method of claim 14 wherein ~~the~~ each dose is in the range from about 50mg/m^2 to about 200mg/m^2.

16. (Previously presented) The method of claim 1 comprising administering an initial dose of the antibody followed by a subsequent dose, wherein the mg/m^2 dose of the antibody in the subsequent dose exceeds the mg/m^2 dose of the antibody in the initial dose.

Claims 17-21. (Cancelled)

22. (Currently amended) The method of claim 1 comprising administering the antibody to the ~~mammal~~ human before the ~~mammal~~ human is exposed to the graft.

Claims 23-27. (Cancelled)

28. (Currently amended) A method of treating graft-versus-host or host-versus-graft disease in a human, wherein the graft is from a human having the same or a different genetic origin as the human being treated, comprising intravenously administering to the human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein after a first intravenous administration of said antibody, the circulating levels of B cells in the human are reduced to treat said disease.

Claims 29-31. (Cancelled)

32. (Previously presented) The method of claim 10, wherein the antibody comprises Y2B8.

33. (Previously presented) The method of claim 10, wherein the antibody comprises ^{131}I-B1.

34. (Previously presented) The method of claim 1, wherein the antibody is a human antibody.

35. (Previously presented) The method of claim 1, wherein the antibody is a chimeric antibody.

36. (Previously presented) The method of claim1, wherein the antibody is a humanized antibody.

37. (Previously presented) The method of claim 28, wherein the antibody is a human antibody.

38. (Previously presented) The method of claim 28, wherein the antibody is a chimeric antibody.

39. (Previously presented) The method of claim 28, wherein the antibody is a humanized antibody.

40. (Previously presented) The method of claim 28, wherein the antibody comprises rituximab.

41. (Previously presented) The method of claim 28, wherein the antibody comprises Y2B8.

42. (Previously presented) The method of claim 28, wherein the antibody comprises ^{131}I-B1.

43. (Currently amended) The method of claim 1, wherein ~~the~~ each dose of the antibody is substantially less than 375 mg/m^2.

44. (Currently amended) The method of claim 28, wherein ~~the~~ each dose of the antibody is substantially less than 375 mg/m^2.

45. (Currently amended) A method of blocking an immune response to an allogeneic graft in a human, where the human is not suffering from a malignancy, ~~comprising~~ consisting essentially of administering to the ~~mammal~~ human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein each administration of the antibody is by intravenous injection.

46. (Currently amended) A method of treating graft-versus-host or host-versus-graft disease in a human, wherein the graft is from a human having the same or a different genetic origin as the human being treated, ~~comprising~~ consisting essentially of administering intravenously to the human more than one dose of a therapeutically effective amount of an antibody which binds to the CD20 antigen on human B lymphocytes, wherein each administration of the antibody is by intravenous injection.

47. (Previously presented) The method of claim 45, wherein the antibody is a chimeric antibody.

48. (Previously presented) The method of claim 45, wherein the antibody is a humanized antibody.

49. (Previously presented) The method of claim 45, wherein the antibody is rituximab.

50. (Currently amended) The method of claim 45, ~~comprising administering a~~ wherein each dose ~~of~~ is in the range from about 20mg/m^2 to about 1000mg/m^2 of the antibody to the ~~mammal~~ human.

51. (Currently amended) The method of claim ~~1~~ 45, wherein ~~the~~ each dose of the antibody is substantially less than 375 mg/m^2.

52. (Currently amended) The method of claim 45 wherein ~~the~~ each dose is in the range from about 20mg/m^2 to about 250mg/m^2.

53. (Currently amended) The method of claim 45 wherein ~~the~~ each dose is in the range from about 50mg/m^2 to about 200mg/m^2.

54. (Previously presented) The method of claim 46, wherein the antibody is a chimeric antibody.

55. (Previously presented) The method of claim 46, wherein the antibody is a humanized antibody.

56. (Previously presented) The method of claim 46, wherein the antibody is rituximab.

57. (Currently amended) The method of claim ~~45~~ 46, ~~comprising administering a~~ wherein each dose ~~of~~ is in the range from about 20mg/m^2 to about 1000mg/m^2 of the antibody to the mammal.

58. (Currently amended) The method of claim ~~1~~ 46, wherein ~~the~~ each dose of the antibody is substantially less than 375 mg/m^2.

59. (Currently amended) The method of claim ~~45~~ 46 wherein ~~the~~ each dose is in the range from about 20mg/m^2 to about 250mg/m^2.

60. (Currently amended) The method of claim ~~45~~ 46 wherein ~~the~~ each dose is in the range from about 50mg/m^2 to about 200mg/m^2.

61. (New) A method of desensitizing a mammal awaiting transplantation comprising administering to the mammal a therapeutically effective amount of an antagonist which binds to CD20.